Use of lipid in amphotericin B infusion has no benefit

Use of lipid in amphotericin B infusion has no benefit

On p 379 Schöffski et al present their results of a randomised phase II study comparing the feasibility of treatment with,and safety and toxicity of, amphotericin B 0.75 mg/kg/day in eitherglucose 5% or intralipid 20%, for the empirical treatment of neutropeniccancer patients with refractory fever of unknown origin or pneumonia.The trial did not confirm previous observations of improved renaltoxicity and better tolerance with amphotericin B in intralipidemulsions, but showed potential respiratory complications fromself made lipid emulsions. The drug combination has high toxicityand unknown efficacy and should not be given to patients.

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

Technorati What's this?

Relevant Article

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study: Patrick Schöffski, Mathias Freund, R Wunder, D Petersen, C H Köhne, H Hecker, U Schubert, and A Ganser
BMJ 1998 317: 379-384. [Abstract] [Full Text] [PDF]